SAGE241220P15000
- 0.00
- 0.000.00%
Sage Therapeutics Newsroom
Sage Therapeutics Drug's Failure in Huntington's 'Not Surprising,' RBC Says
Express News | TD Cowen Maintains Hold on Sage Therapeutics, Lowers Price Target to $9
This Palo Alto Networks Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday
Sage Raised to Sector Perform by RBC in Wake of Drug Failure
SAGE's Dalzanemdor Fails to Meet Goal in Huntington's Disease Study
A Quick Look at Today's Ratings for Sage Therapeutics(SAGE.US), With a Forecast Between $4 to $14
Truist Financial Sticks to Their Hold Rating for SAGE Therapeutics (SAGE)
Sage Therapeutics Price Target Lowered to $4 From $7 at BofA
RBC Upgrades SAGE Therapeutics to Sector Perform From Underperform, Keeps Speculative Risk, $4 Price Target
SAGE Therapeutics: Analyst Reiterates Sell Rating Amid Pipeline Setbacks and Prescriber Challenges
Express News | RBC Capital Upgrades Sage Therapeutics to Sector Perform, Maintains Price Target to $4
SAGE Therapeutics: Hold Rating Amid Dalzanemdor's Phase 2 Failure and Valuation Adjustments
Sage Therapeutics Reported Another Clinical Setback, Says H.C. Wainwright
Express News | Sage Therapeutics Shares Reverse Course; Last up 4.3%
Wedbush Cuts Price Target on SAGE Therapeutics to $4 From $7, Maintains Neutral Rating
Sector Update: Health Care Stocks Edge Higher Premarket Wednesday
Cracking The Code: Understanding Analyst Reviews For Sage Therapeutics
Exchange-Traded Funds, Equity Futures Higher Pre-Bell as Traders Await Nvidia Earnings
Express News | Needham Reiterates Hold on Sage Therapeutics
Sage Therapeutics Analyst Ratings